Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

Background: We planned to compare pemetrexed maintenance with erlotinib maintenance in non squamous non Epidermal Growth Factor Receptor (EGFR) mutated non small cell lung cancer (NSCLC). The null hypothesis for this study was that there would be no difference in quality of life (QOL) between pemetr...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Vijay, Joshi, Amit, Noronha, Vanita, Agarwala, Vivek, Chougule, Anuradha, Kanan, Sadhana, Bhattacharjee, Atanu, Chandrasekharan, Arun, Pande, Nikhil, Simha, Vijai, Goud, Supriya, More, Sucheta, Kumar, Rajiv, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824869/
https://www.ncbi.nlm.nih.gov/pubmed/31695838
http://dx.doi.org/10.18632/oncotarget.27214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824869/
https://www.ncbi.nlm.nih.gov/pubmed/31695838
http://dx.doi.org/10.18632/oncotarget.27214

Ejemplares similares